Immune Defense Stack
Dual-pathway immune modulation
Why This Stack Works
Thymosin Alpha-1 modulates T-cell activity and enhances antigen presentation — the adaptive immune response. LL-37 provides broad-spectrum antimicrobial action and activates the innate immune system. Together they reinforce both branches of immunity.
This combination draws from Immune research, targeting immune, T-cell, thymus, adaptive immunity, infection, healing. The compounds in this stack act on distinct receptor systems and biological pathways, making them suitable for combined use without mechanism overlap.
All compounds in this stack are supplied by Phiogen with independent third-party Certificate of Analysis (COA) documentation confirming 99%+ purity. They are sold strictly for laboratory and educational use only and are not FDA-approved for human therapeutic use.
Research Protocol
Thymosin Alpha-1: 1–1.6 mg 2×/week SC. LL-37: 100–200 mcg/day SC. Duration: 4–8 weeks.
Stack Components
Thymosin Alpha-1 10mg
ImmuneThymic peptide for T-cell activation, immune enhancement, and adaptive immunity.
- T-cell maturation and activation
- Adaptive immune enhancement
- Chronic infection resistance
- Innate immune modulation
LL-37 10mg
ImmuneHuman cathelicidin antimicrobial peptide with immune modulation and wound healing properties.
- Broad-spectrum antimicrobial activity
- Immune system modulation
- Wound healing promotion
- Chronic inflammation reduction
Frequently Asked Questions
What is the Immune Defense Stack?
The Immune Defense Stack is a synergistic research peptide protocol designed for dual-pathway immune modulation. Thymosin Alpha-1 modulates T-cell activity and enhances antigen presentation — the adaptive immune response. LL-37 provides broad-spectrum antimicrobial action and activates the innate immune system. Together they reinforce both branches of immunity.
What is the protocol for the Immune Defense Stack?
Thymosin Alpha-1: 1–1.6 mg 2×/week SC. LL-37: 100–200 mcg/day SC. Duration: 4–8 weeks. Note: All compounds are for research and laboratory use only and are not intended for human therapeutic application. Consult the relevant preclinical literature before designing any research protocol.
What compounds are in the Immune Defense Stack?
This stack includes Thymosin Alpha-1 10mg, LL-37 10mg. Key benefits include: Thymosin Alpha-1 10mg: T-cell maturation and activation; LL-37 10mg: Broad-spectrum antimicrobial activity. Each compound targets a distinct mechanism, making them suitable for combined research use without pathway redundancy.
Explore More Stacks
Browse all 9 synergistic peptide protocols or explore the full product catalog.